Product Images Fesoterodine Fumarate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Fesoterodine Fumarate NDC 42291-054 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
30 - 053 30
Each extended-release, film-coated tablet contains 4 mg of fesoterodine fumarate. The usual dosage is extended-release. The tablets should be stored at a temperature of 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). It is important to protect them from moisture. The prescription should be dispensed with the L&D vantactred and a patient information leaflet. This product is manufactured by Amneal Pharmaceuticals New York, LLC.*
30 - 054 30
NDC 42291-054-30 is a medication called Fesoterodine Fumarate, which is available in the form of extended-release tablets. Each tablet contains 8 mg of fesoterodine fumarate. This medication requires a prescription and should be dispensed by a pharmacist along with a patient information leaflet. The usual dosage should be determined based on the accompanying prescribing information. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). It is important to protect the medication from moisture. The medication is manufactured for AVKARE in Pulaski, TN 38478, and manufactured by Amneal Pharmaceuticals of New York, LLG in Brookhaven, NY 11719.*
Structural Fomula - fesoterodine fumarate extended release tablets 1
figure 1 - fesoterodine fumarate extended release tablets 2
This text provides information on the mean change from baseline in the number of micturitions per 24 hours. It appears to be related to a study (Study 1) evaluating the effects of different treatments. The treatments mentioned are a placebo and two doses of fesoterodine fumarate (4 mg and 8 mg). The data is presented in Figure 1, showing the change in the number of micturitions over the course of weeks 2, 8, and 12.*
figure 2 - fesoterodine fumarate extended release tablets 3
Mean change from baseline in urge incontinence episodes per 24 hours was evaluated in a study. The results are presented in Figure 2, showing the changes over the course of 12 weeks. The study included three groups: a placebo group (N=211), a group receiving fesoterodine fumarate 4 mg (N=199), and a group receiving fesoterodine fumarate 8 mg (N=223).*
figure 3 - fesoterodine fumarate extended release tablets 4
Not available.*
figure 4 - fesoterodine fumarate extended release tablets 5
This text provides information on the mean change from baseline in urge incontinence episodes per 24 hours in a study. It also includes a figure (Figure 4) showing the change in urge incontinence episodes over different weeks. The text mentions a placebo group (N=205) and two different doses of fesoterodine fumarate (4 mg with N=228 and 8 mg with N=218).*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.